Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17911615 | 0.89 | ALDH1A3 (0.41) | KMT2AALDH1A1POLBCA1CA2 | |
| SCHEMBL6516593 | 0.80 | ACHE (0.46) | ACHEKMT2AMEN1TDP1CYP3A4 | |
| SCHEMBL28835255 | 0.80 | CA1 (0.55) | ACHETDP1CYP3A4ALDH1A1MAPT | |
| SCHEMBL4163652 | 0.80 | LDHA (0.48) | KMT2AMEN1TDP1TSHRALDH1A1 | |
| SCHEMBL1162019 | 0.79 | ACHE (0.50) | ACHEKMT2AMEN1TDP1CYP3A4 | |
| SCHEMBL104201 | 0.79 | ALDH1A3 (0.54) | ACHEKMT2AMEN1TDP1CYP3A4 | |
| SCHEMBL11239191 | 0.78 | ESR2 (0.46) | KMT2AMEN1TDP1CYP3A4ALDH1A1 | |
| SCHEMBL14150498 | 0.78 | SLC2A1 (0.41) | KMT2AMEN1TDP1TSHRALDH1A1 | |
| SCHEMBL3053959 | 0.78 | ALDH1A1 (0.47) | ACHEKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6802075 | 0.78 | POLB (0.47) | ALDH1A1POLBLMNASLC6A4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488748-B2 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-10 | — | — | US | disclosed |
| CN-101230049-A | Hydroxamic acid histone deacetylase inhibitor as well as preparation method and use thereof | UNIV CHINA PHARMA (CN) | 2008-07-30 | — | — | CN | disclosed |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-02 | — | — | US | disclosed |
| EP-1590325-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067510-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | ACHE 62/4885KMT2A 3801/4885MEN1 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.